retatrutide injection pen Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Remedium Research Retatrutide Pen Guide

OdoriSHosodaKTomitaTFujikuraJKusakabeTKawaguchiYet al

17 Recent advances in pharmacological treatments Sodium-glucose cotransporter-2 inhibitors SGLT-2 inhibitors (empagliflozin and dapagliflozin) are recommended in most people with type 2 diabetes and CKD, given the strong evidence that SGLT-2 inhibitors reduce CKD progression, heart failure and the risk of atherosclerotic CV disease in people with type 2 diabetes and CKD

Prior to that, the treatment of obesity has been predominantly limited to lifestyle interventions and bariatric surgery

however, no approved therapy simultaneously targets these interconnected mechanisms

A 2022 clinical trial funded by Novo Nordisk (which makes Ozempic and Wegovy) found that a weekly dose of one GLP-1 drug reduced heavy-drinking days and total intake for people struggling with alcohol use disorder but only in a subgroup of patients with a BMI over 30

Lancet (2016) 388(10053):1659724